Search Results 61-70 of 16588 for Certolizumab

  1. Smallpox and mpox vaccine, live (intradermal route, subcutaneous route) - Mayo Clinic

    Baricitinib; Belatacept; Betibeglogene Autotemcel; Bimekizumab-bkzx; Brodalumab; Canakinumab; Certolizumab Pegol; Cyclosporine; Deucravacitinib; Deuruxolitinib ...

  2. A Study of CMB305 and Atezolizumab in Patients with Sarcoma - Mayo Clinic

    CMB305 is a novel approach designed to stimulate the body's immune system to fight the spread and growth of cancer in patients whose tumors express the NY-ESO-1 ...

  3. A Study to Test the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer - Mayo Clinic

    Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as ...

  4. Back Pain Clinical Trials - Mayo Clinic Research

    ... certolizumab pegol (CZP) 200 mg every two weeks or placebo. The primary objective is to demonstrate the efficacy of CZP in these patients. A Study Comparing ...

  5. A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower130) - Mayo Clinic

    This randomized Phase III, multicenter, open-label study is designed to evaluate the safety and efficacy of atezolizumab in combination with carboplatin + nab- ...

  6. A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma - Mayo Clinic

    About this study. Primary Objective: - Part A: To evaluate the safety of SAR650984 (isatuximab) in patients with relapsed/refractory multiple myeloma (RRMM) ...

  7. Rilonacept in Subjects with Cardiac Sarcoidosis - Mayo Clinic

    TNF inhibitors within 2-8 weeks of or 5 half-lives (etanercept within 2 weeks; infliximab, certolizumab, golimumab, or adalimumab within 8 weeks) prior to ...

  8. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy - Mayo Clinic

    ... certolizumab pegol). Exclusion Criteria: Subjects with ulcerative colitis (UC), collagenous colitis or indeterminate colitis. Subject who has had surgical ...

  9. Neurology - Clinical trials

    The Parkinson Progression Marker Initiative (PPMI) is a study to assess progression of clinical features, digital outcomes, and imaging, biologic and ...

  10. Hematology - Clinical trials

    Hematology — Learn about innovative diagnosis and treatment options for blood diseases, including cancers, at Mayo Clinic.